Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma

L. Manenti, P. Paganoni, I. Floriani, F. Landoni, V. Torri, A. Buda, G. Taraboletti, R. Labianca, D. Belotti, R. Giavazzi

Research output: Contribution to journalArticle

Abstract

We measured the levels of the vascular endothelial growth factor (VEGF), matrix metalloproteinases type 2 and type 9 (MMP-2 and MMP-9) and tissue inhibitors of matrix metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) in the plasma of patients with ovarian carcinoma (n=40), in other gynaecological pathologies (n=30) and in the plasma of healthy volunteers (n=26). MMP-2 and MMP-9 (pro and active forms) gelatinolytic activity was measured by zymography. Enzyme-linked immunosorbent assays (ELISA) were used to assay soluble VEGF and TIMPs. Preoperative plasma VEGF levels were significantly higher in patients with ovarian cancer than in healthy volunteers (P

Original languageEnglish
Pages (from-to)1948-1956
Number of pages9
JournalEuropean Journal of Cancer
Volume39
Issue number13
DOIs
Publication statusPublished - Sep 2003

Keywords

  • MMP-2
  • MMP-9
  • Ovarian carcinoma
  • TIMP-1
  • TIMP-2
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma'. Together they form a unique fingerprint.

  • Cite this